ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bofanglutide

Also written as “GZR18”, “GZR18 injection” and “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive, led by 2 companies.

Drug pageBofanglutide: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 5, 202425 company-led studies, 9 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticals237 open or runningphase 3since Dec 5, 2024Feb 25, 2022Jun 30, 2027phase 3 · NCT07150975
Carnot Laboratoriesits history only22 open or runningphase 3since May 24, 2026May 24, 2026Oct 2027phase 3 · NCT07628985

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gan & Lee Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 25, 2022First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05328726 · 24 enrolled · United States
  2. Feb 5, 20244 phase 2 studiesNCT06256562, NCT06256549, NCT06256536 and 1 more
  3. Feb 29, 2024Named bofanglutideINNProposed as its International Nonproprietary Name in WHO's List 130
  4. Aug 8, 20243 phase 1 studiesNCT06554054, NCT06548997, NCT06548945
  5. Oct 29, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06670209 · 32 planned
  6. Dec 5, 2024Phase 3 study in ObesityNCT06728124 · 640 enrolled · China
  7. Dec 16, 2024Phase 2 study in ObesityNCT06737042 · 326 enrolled · United States
  8. Jan 3, 20252 phase 3 studies in Diabetes Mellitus, Type 2NCT06778967, NCT06777238
  9. Jun 27, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07055386 · 90 enrolled · China
  10. Jul 9, 2025Phase 1 study in OverweightNCT07119450 · 6 enrolled · China
  11. Aug 6, 20253 phase 1 studies in ObesityNCT07128888, NCT07141030, NCT07144098
  12. Aug 27, 2025Phase 3 study in ObesityNCT07150975 · 420 planned · China
  13. Nov 20, 2025Phase 3 study in OverweightNCT07292441 · 224 enrolled · China
  14. Jan 5, 2026Phase 1 study in Obesity&T2DNCT07355738 · 266 enrolled · China
  15. Mar 20, 20262 phase 3 studies in Sleep Apnea, ObstructiveNCT07493057, NCT07501832

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in ObesityNCT07150975
  2. Nov 14, 2027Primary completion: phase 3 study in Sleep Apnea, ObstructiveNCT07493057
  3. Sep 28, 2028Primary completion: phase 3 study in Sleep Apnea, ObstructiveNCT07501832

TargetBeta

GLP1R →read by rule
“Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 23 Gan & Lee Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07501832Sleep Apnea, Obstructive · China3RecruitingSep 28, 2028140
NCT07493057Sleep Apnea, Obstructive · China3RecruitingNov 14, 2027140
NCT07355738Obesity&T2D · China1CompletedMay 22, 2026266
NCT07292441Overweight · China3CompletedSep 22, 2026224
NCT07150975Obesity · China3RecruitingJun 30, 2027420
NCT07144098Obesity · China1CompletedApr 7, 202624
NCT07141030Obesity · China1CompletedOct 20, 202532
NCT07128888Obesity · China1CompletedApr 13, 202660
NCT07119450Overweight · China1CompletedAug 13, 20256
NCT07055386Diabetes Mellitus, Type 2 · China2Active, not recruitingJun 28, 202690
NCT06777238Diabetes Mellitus, Type 2 · China3CompletedJul 30, 2026274
NCT06778967Diabetes Mellitus, Type 2 · China3CompletedSep 18, 20261,133
NCT06737042Obesity · United States2CompletedFeb 27, 2026326
NCT06728124Obesity · China3CompletedMar 26, 2026640
NCT06670209Diabetes Mellitus, Type 21Not yet recruitingMar 19, 202532
NCT06554054Diabetes Mellitus, Type 2 · China1Active, not recruitingDec 9, 202492
NCT06548997Diabetes Mellitus, Type 2 · China1CompletedOct 20, 202257
NCT06548945Overweight · China1CompletedAug 14, 202316
NCT06256562Obesity · China2CompletedJun 5, 2024340
NCT06256549Diabetes Mellitus, Type 2 · China2Active, not recruitingJul 20, 2024272
NCT06256536Obesity · China2CompletedOct 22, 202360
NCT06256523Diabetes Mellitus, Type 2 · China2CompletedSep 28, 202372
NCT05328726Diabetes Mellitus, Type 2 · United States1CompletedFeb 9, 202324

How it is read

Names in the registry

  • “GZR18”, 13 entries
  • “GZR18 injection”, 8 entries
  • “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”, 1 entry
  • “GZR18 injection A”, 1 entry
  • “GZR18 injection B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.